Table 4 Characteristics of patients treated with MRgFUS, UAE and Myomectomy
From: Cost comparison between uterine-sparing fibroid treatments one year following treatment
Patient characteristics | MRgFUS | UAE | Myomectomy | P-Valuea |
|---|---|---|---|---|
(N = 14) | (N = 4,092) | (N = 10,320) | ||
Age | ||||
25-34 | 0.0% | 4.0% | 33.1% | |
35-44 | 28.6% | 46.4% | 55.3% | |
45-54 | 71.4% | 49.7% | 11.6% | 0.000 |
Region | ||||
Northeast | NR | 13.8% | 14.2% | |
Midwest | NR | 18.8% | 15.0% | |
South | NR | 52.4% | 54.5% | |
West | NR | 14.2% | 15.7% | |
Unknown | NR | 0.7% | 0.6% | 0.000 |
Employment details | ||||
Employee (not spouse or dependent) | 64.3% | 71.7% | 77.5% | 0.000 |
Plan type | ||||
Fee for service | 7.1% | 3.9% | 3.0% | |
HMO | 28.6% | 29.3% | 24.4% | |
Point of Service (POS) | 7.1% | 13.0% | 15.0% | |
Preferred Provider Organization | 57.1% | 47.9% | 51.7% | |
Capitated POS | 0.0% | 2.4% | 2.0% | |
Consumer Driven Health Plan (CDHP) | 0.0% | 2.1% | 2.6% | 0.000 |
Year of index date | ||||
2004 | 0.0% | 7.4% | 10.8% | |
2005 | 7.1% | 13.8% | 13.4% | |
2006 | 14.3% | 15.2% | 14.4% | |
2007 | 28.6% | 16.5% | 17.1% | |
2008 | 21.4% | 19.0% | 19.5% | |
2009 | 21.4% | 27.4% | 24.2% | 0.000 |
Sociodemographics of ZIP Code of residence | ||||
Median household income | ||||
Quintile 1 ($0,$28,280) | 0.0% | 8.3% | 9.2% | |
Quintile 2 ($28,281, $33,680) | 7.1% | 8.3% | 9.5% | |
Quintile 3 ($33,681, $39,204) | 14.3% | 16.4% | 16.5% | |
Quintile 4 ($39,205, $48,749) | 35.7% | 19.2% | 21.1% | |
Quintile 5 (≥$48,750) | 42.9% | 47.8% | 43.7% | 0.001 |
% over 25 with college degree | ||||
Quintile 1 (0-7%) | 0.0% | 0.2% | 0.3% | |
Quintile 2 (8-11%) | 0.0% | 2.3% | 2.6% | |
Quintile 3 (12-15%) | 14.3% | 13.5% | 13.2% | |
Quintile 4 (16-24%) | 71.4% | 29.7% | 31.0% | |
Quintile 5 (≥25%) | 14.3% | 54.2% | 52.9% | 0.333 |
% Black | ||||
Quintile 1 (0%) | 0.0% | 3.7% | 3.5% | |
Quintile 2 (0.1-0.3%) | 0.0% | 7.3% | 7.8% | |
Quintile 3 (0.4-1.3%) | 28.6% | 15.5% | 15.6% | |
Quintile 4 (1.4-8.5%) | 14.3% | 22.2% | 23.6% | |
Quintile 5 (≥8.6%) | 57.1% | 51.2% | 49.5% | 0.050 |
Surgical setting | ||||
Inpatient | 0.0% | 18.3% | 74.6% | |
Outpatient | 100.0% | 81.7% | 25.4% | 0.000 |
Use of pharmacotherapy during baseline | ||||
NSAIDs (non-steroidal anti-inflammatories) | 35.7% | 27.9% | 24.9% | 0.001 |
Hormone therapy | 42.9% | 31.1% | 40.5% | 0.000 |
Healthcare use during baseline | ||||
Any inpatient visits | 14.3% | 5.7% | 7.0% | 0.010 |
Any ER visits | 50.0% | 20.8% | 24.4% | 0.000 |
Baseline health status | ||||
Avg. Charlson Cormorbidity Index | 0.14 | 0.23 | 0.17 | |
Charlson Cormorbidity Index >0 | 14.3% | 16.0% | 12.8% | 0.000 |
Avg. Number of Psychiatric Diagnostic Groupings | 2.57 | 2.06 | 2.81 | |
Number of Psychiatric Diagnostic Groupings >1 | 50.0% | 58.5% | 76.4% | 0.000 |
Menstrual disorders | 64.3% | 56.3% | 45.9% | 0.000 |
Pelvic pain | 42.9% | 24.0% | 31.3% | 0.000 |
Anemias | 7.1% | 28.4% | 17.9% | 0.000 |
Inflammatory disease | 28.6% | 14.2% | 18.4% | 0.000 |
Noninflammatory disease | 7.1% | 14.0% | 17.6% | 0.000 |
Endometriosis | 0.0% | 2.2% | 5.2% | 0.000 |
Pregnancy | 7.1% | 2.9% | 15.2% | 0.000 |
Urinary problems | 0.0% | 3.4% | 3.7% | 0.508 |
Constipation or gas | 7.1% | 2.8% | 2.9% | 0.605 |
Other disorders of the uterus | 14.3% | 19.4% | 13.3% | 0.000 |
Genital prolapse | 0.0% | 0.5% | 0.6% | 0.745 |
Benign neoplasm of the uterus | 0.0% | 0.1% | 0.5% | 0.003 |
Infertility | 0.0% | 1.0% | 14.8% | 0.000 |
Breast cancer | 0.0% | 0.6% | 0.5% | 0.729 |
a. P-value from chi-square test of significance of difference between the groups | ||||
NR = not reportable due to small sample size | ||||